Key result
Emergent subxiphoid pericardial window restores hemodynamics after apixaban-induced hemorrhagic tamponade in a dialysis patient.
Why the study?
Randomized trial data for direct oral anticoagulants in AF patients receiving hemodialysis remain limited, and the anticoagulant effect of a given dose varies considerably between patients.
Case Report (n=1)
No
This case illustrates the life-threatening risk of hemorrhagic cardiac tamponade in a hemodialysis patient receiving full-dose apixaban (5 mg twice daily) and underscores the critical role of bedside ultrasound in diagnosing obstructive shock when symptoms mimic dialysis-associated hypotension or sepsis.
Answers are grounded in this paper and cite their sources.
Warrants caution with full-dose apixaban in hemodialysis; leaves open optimal dosing strategies for prospective study.
Direct oral anticoagulants are used for stroke prevention in selected patients with atrial fibrillation who receive hemodialysis. Randomized trial data remain limited in this population, and the anticoagulant effect of a given dose may vary considerably between patients. We report a 56-year-old man receiving hemodialysis three times weekly who was taking apixaban 5 mg twice daily and developed persistent hypotension and abdominal pain during dialysis. The early findings suggested dialysis-associated hypotension or sepsis. Emergency department point-of-care cardiac ultrasound showed a large circumferential pericardial effusion, leading to urgent cardiology evaluation for obstructive shock. Computed tomography obtained during the same evaluation described the effusion as large and possibly hemorrhagic. Pericardiocentesis was unsuccessful because most of the fluid was posterior. Shortly after transfer to the intensive care unit, the patient developed pulseless electrical activity arrest and underwent an emergent subxiphoid pericardial window. Approximately 450 mL of bloody fluid was drained, followed by hemodynamic improvement. Cytology showed no malignant cells, and fluid cultures were negative. This case also highlights the uncertainty surrounding the use of full-dose apixaban in patients receiving hemodialysis, particularly after a major bleeding event.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a case report in Hemorrhagic cardiac tamponade in end-stage renal disease with chronic nonvalvular atrial fibrillation (n=1). Apixaban was evaluated on Resolution of hemorrhagic cardiac tamponade via emergent subxiphoid pericardial window. Emergent subxiphoid pericardial window drained 450 mL of bloody fluid and restored hemodynamics after full-dose apixaban was complicated by hemorrhagic tamponade and PEA arrest in a dialysis patient.
Synapse has enriched 10 related papers. Consider them for comparative context: